Mn Services Vermogensbeheer B.V. Decreases Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mn Services Vermogensbeheer B.V. lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 82,200 shares of the medical equipment provider’s stock after selling 2,300 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Zimmer Biomet were worth $8,921,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of ZBH. OLD Point Trust & Financial Services N A purchased a new stake in Zimmer Biomet during the 4th quarter worth about $26,000. Ables Iannone Moore & Associates Inc. purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth approximately $30,000. Crewe Advisors LLC purchased a new stake in shares of Zimmer Biomet during the first quarter worth approximately $31,000. Family Firm Inc. acquired a new stake in Zimmer Biomet in the second quarter valued at approximately $33,000. Finally, J.Safra Asset Management Corp lifted its stake in Zimmer Biomet by 712.1% in the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 235 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Canaccord Genuity Group reduced their price objective on shares of Zimmer Biomet from $130.00 to $120.00 and set a “hold” rating on the stock in a report on Tuesday, August 20th. UBS Group cut their price target on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research note on Thursday, August 8th. Evercore ISI lowered their price objective on Zimmer Biomet from $115.00 to $113.00 and set an “in-line” rating for the company in a research report on Thursday, August 8th. Barclays decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. Finally, Argus upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a research note on Tuesday, May 21st. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $127.11.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $115.05 on Monday. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $133.90. The stock’s 50-day moving average price is $108.98 and its 200 day moving average price is $117.60. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $23.67 billion, a PE ratio of 24.90, a price-to-earnings-growth ratio of 2.02 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same quarter in the previous year, the company posted $1.82 earnings per share. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.06 EPS for the current year.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.